[An English cohort study endorses sildenafil. No indication of increased cardiovascular risk].
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D000075202:Contraindications; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D010919:Placebos; D011320:Primary Health Care; D011687:Purines; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones; D006113:United Kingdom; D014665:Vasodilator Agents / Q000009:adverse effects*
D010879:Piperazines; D010919:Placebos; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate